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PEE8
QUALITY OF LIFE OF FRENCH PATIENTS 
TREATED FOR PRIMARY OPEN ANGLE 
GLAUCOMA AND OCULAR HYPERTENSION
Auzanneau N1, Touboul C1, Berdeaux G2
1Taylor Nelson Sofres, Montrouge, France; 2Alcon, Rueil-
Malmaison, France
OBJECTIVE: The aim of this study was to evaluate the
quality of life (QoL) of patients treated with a topical
anti-glaucoma drug in usual practice.
METHODS: A mailing was sent to 20,000 homes be-
longing to the Sofres panel (representative to the French
population according to the quota method) asking whether
one member of the family was treated for glaucoma. A
computer-assisted telephone interviewing system was
used to confirm self-reported glaucoma treatment, to de-
scribe the disease and its treatment, as well as medical
item consumption. Vision-related QoL was assessed with
the NEI-VFQ-25 and local tolerance and its QoL conse-
quences with the COMTOL.
RESULTS: 13,352 homes (66.7%) or 32,685 people an-
swered the mail. Five hundred eighty one people declared
they had glaucoma, leading to glaucoma and ocular hy-
pertension treatment prevalence of 1.8%, increasing with
age. From them, 204 people were selected at random.
Their NEI-VFQ-25 global score was high (80.2) showing
an overall good QoL. Two scores showed some deterio-
ration: general health (48.8) and driving (53.9). Ninety-
one (44.6%) patients changed their treatment at least
once: 55% due to poor efficacy and 35% for adverse
events. Being queried with the COMTOL, 62% of the
patients cited at least one local adverse event: 25% had
burning, 21% blurred vision, 20% tearing and 16% itch-
ing among others. Sixty percent of the patients visited
their ophthalmologist twice a year and 90% of the pa-
tients declared they were satisfied or very satisfied with
their treatment.
CONCLUSION: Based on a French representative sam-
ple, the overall satisfaction of patients treated with anti-
glaucoma drugs is high, although half of them have
changed their treatment at least once and the majority of
them declared an adverse event when queried. Eye related
QoL was not affected in the majority of the patients.
PEE9
THE SOCIETAL COST OF ATOPIC DERMATITIS 
IN GERMANY
Banz K1, Klein W2, Brunella A1
1Outcomes International, Basel, Switzerland; 2Fujisawa GmbH, 
Munich, Germany
Atopic dermatitis (AD) is a common chronic dermatolog-
ical disease affecting mainly young children. According to
epidemiological studies, its prevalence has increased no-
tably over the last two decades.
OBJECTIVE: To assess the economic burden of AD in
Germany.
METHODS: A prevalence approach was adopted to
evaluate the societal cost of AD comprising direct medi-
cal costs, indirect costs, and out-of-pocket expenses. Not
included in this evaluation is the impact of AD on the pa-
tient and the family in terms of an impaired quality of
life. Data were collected from various sources: health sta-
tistics; labor statistics; literature; surveys, and an expert
panel of six dermatology specialists. All costs were ad-
justed to the year 1999. In order to explore the findings
in light of data variations, sensitivity analyses were per-
formed.
RESULTS: Based on an estimated base case population
of 2.45 million people suffering from AD, total annual
societal costs amount to DEM 1.32 billion (EUR 678 mil-
lion). Of these overall costs, DEM 636 million (48%) are
attributable to direct costs, DEM 428 million (32%) to
productivity losses (including time expenditures of par-
ents caring for their sick children), and DEM 257 million
(20%) to out-of-pocket expenses. The most important in-
dividual cost contributor is outpatient physician care
(28%), followed by time expenditure of parents (20%),
and out-of-pocket expenses (19%). Drug treatment ac-
counts for less than 10% of the overall costs. The average
per-patient societal cost of AD is around DEM 540 per
year. Sensitivity analysis showed a maximum variation in
yearly costs ranging between DEM 1.08 billion and DEM
1.61 billion when both prevalence and utilization esti-
mates are varied.
CONCLUSIONS: The chronic nature of AD coupled with
its high frequency represents a significant economic burden
to society in Germany. Based on these findings it can be
concluded that AD cannot be regarded as a minor illness.
PEE10
IS NON-CONTACT NORMOTHERMIC WOUND 
THERAPY COST-EFFECTIVE FOR THE 
TREATMENT OF STAGE 3 AND 4 
PRESSURE ULCERS?
Macario A1, Dexter F2
1Stanford University, Stanford, CA, USA; 2Univeristy of Iowa, 
Iowa City, IA, USA
OBJECTIVES: Chronic pressure ulcers are a significant
health problem for patients in long-term-care facilities.
The value of restoring quality of life following a pressure
ulcer injury has attracted new treatments. Non-contact
normothermic wound therapy (NNWT) (Warm-Up ther-
apy) is a semi-occlusive, moisture retentive wound cover
($240/wound cover/ 2 days) that is warmed to 38	C to
promote healing. The goal of this study was to examine
the incremental cost-effectiveness of NNWT relative to
the current standard of care for treatment of stage III and
IV pressure ulcers.
METHODS: A Markov cost-effectiveness, computer-sim-
ulation model with hypothetical patients was created.
The base case involved a 72-year-old man, living in a
nursing home, with a stage III ischial pressure ulcer.
Standard care was assumed to include moisture retentive
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dressings, a pressure reducing surface, repositioning, and
debridement.
RESULTS: Our modeling predicted the total expected cost
of standard care treatment for a stage 3 pressure ulcer to
be $20,874. Randomized clinical trials have found that
NNWT (n  72 patients) decreases the surface area of
stage 3-4 pressure ulcers by 2.5 fold (SD 59%) over stan-
dard care (n  59 patients). The eight-week healing rates
for stage 3 ulcers are 71% with NNWT and 54% for stan-
dard care. At these healing rates, our modeling for stage 3
pressure ulcers found that for a 40 month time frame
NNWT saves $6,630 (SE $98) and increases QALYs by
0.10 (SE 0.0005) life years compared to standard care. For
stage 4 pressure ulcers, NNWT saves $15,216(SE $186)
and increases QALYs by 0.14 (SE 0.001).
CONCLUSIONS: NNWT in patients with stage 3 and 4
pressure ulcer is an economically attractive intervention.
Additional well-controlled clinical trials are necessary to
further define the role of NNWT in the care of chronic
wounds.
PEE11
PSORIASIS AND EVERYDAY LIFE: 
FIRST RESULTS
Corvest M1, Lefrançois P2, Myon E3, Taïeb C3 
1Association Pour La Lutte Contre Le Psoriasis, Eragny, France; 
2Pierre Fabre Dermatologie, Lavaur, France; 3bioMérieux-Pierre 
Fabre, Boulogne Billancourt, France
Psoriasis is a chronic disease, which affects 4.7 % of the
French population. Even if it is not a question of a vital
prognosis, it is a very invalidating condition in daily life
because of the damage to the body image.
OBJECTIVE: Evaluate the Quality of Life consequences
for patients with psoriasis, in France.
METHOD: Four thousand five hundred anonymous
questionnaires were sent, via a Patient Support Group
acting against Psoriasis (Association Pour la Lutte Contre
le Psoriasis, APLCP). The questionnaires consisted of two
scales: the Psoriasis Disability Index and 10 questions
concerning the treatment and evolution of psoriasis.
RESULTS: Twenty-five days after the mailing, 2014
questionnaires (44%) were received. An analysis of the
first questionnaire was conducted. The respondents were
54% women, average age was 50 years, and for men, 53
years. The average age at diagnosis for men was 30 years,
and for women, 25 years. Women are significantly more
adversely affected than men in their everyday activities.
Men are significantly more adversely affected than women
at work. No difference was observed between men’s and
women’s global scores. Psoriasis seems to incapacitate 16
to 55 year olds in their social relations, leisure activities
and how well they keep their house more than it does
older subjects. Long-standing psoriasis does not seem to
be more of a handicap to people than more recent psoria-
sis. The global score is similar. However, a clear trend is
observed between the age at the moment of diagnosis and
the level of incapacity (p  .0176). The younger the indi-
vidual in which psoriasis is diagnosed, the higher the level
of incapacity. This is particularly marked in terms of the
everyday and leisure scores.
CONCLUSION: These results highlight the value of ap-
propriate and relevant psychological and medical envi-
ronment for children suffering from psoriasis.
PEE12
THE WILLINGNESS TO PAY FOR 
PHARMACOTHERAPY OF ATOPIC DERMATITIS
Ikeda S1, Tamura M2, Yamaki S3, Nakagawa H4
1Keio University, Tokyo, Japan; 2International University of 
Health and Welfare, Otawara, Japan; 3University of Tokyo, 
Tokyo, Japan; 4Jichi Medical School, Tochigi, Japan
OBJECTIVE: For patients with atopic dermatitis, long-
term treatment is usually unavoidable and various limita-
tions are caused in their daily life. Therefore, the influ-
ence on the patient of new, innovative pharmacotherapy
for atopic dermatitis is thought to be extremely large
from an economic viewpoint. In this study, we attempted
to measure willingness to pay (WTP) for the newly devel-
oped therapeutic agent, “tacrolimus”.
METHODS: 1,000 men and women, 20–59 years old and
living in the Tokyo metropolitan area, were selected by
random sampling for the interview survey. The bidding
game method and the take-it-or-leave-it approaches were
adopted. Eight patterns of health-care costs for one month
(from 625 to 80,000 yen) were allocated to each respon-
dent at random to avoid “starting point bias”. We esti-
mated the demand curve, assuming that the log transfor-
mation of WTP will be distributed as a logistic function.
RESULTS: A total of 431 interviews (43.1% of the can-
didates) were completed. More than half responded as
“yes” to the price of 10,000 yen or less. The demand
curve was estimated to be: P(x)1/(1  exp(5.5239 
0.5906 ln(x))). The median of WTP was 11,537 yen
(95% CI: 8,967–14,845).
CONCLUSION: It can be interpreted that the average
amount people are willing to pay for tacrolimus pharma-
cotherapy is 11,500 yen a month. This information is
considered to be beneficial for clinical decision-making as
well as policy decision-making such as price setting and
reimbursement decisions.
NEUROLOGICAL DISORDERS
PND1
ASSOCIATION OF FAMILY HARDINESS WITH 
WORK PRODUCTIVITY AND ACTIVITY IN 
FAMILIES OF PEDIATRIC PATIENTS WITH 
EPILEPSY
Meek PD, Gidal BE, Sheth R, Hermann BP
University of Wisconsin at Madison, Madison, WI, USA
OBJECTIVE: The Family Hardiness Index (FHI) has
been used to glean insight into the functionality of the
